What are the possible side effects of using latanoprost on the scalp?

Latanoprost is a prostaglandin analog approved for treating glaucoma, where it lowers intraocular pressure. Its unexpected cosmetic effect—stimulating eyelash growth—has shifted attention toward its potential for scalp hair loss treatments. However, because this drug was designed for the eye and not the scalp, the question of side effects becomes central. What is actually known about applying latanoprost to the scalp, and what risks should a reader be aware of?

The short answer is that there is no scalp safety data worth the name. Almost everything below is extrapolated from the ophthalmic label and from one small scalp pilot study, and it should be read that way.

Why a glaucoma drug ended up on the scalp

The interest in latanoprost for hair growth originates from its effect on the hair follicle cycle. Hair follicles operate through phases: growth (anagen), regression (catagen), rest (telogen), and shedding (exogen). Prostaglandins, the compounds latanoprost mimics, influence these transitions. The prescribing information for latanoprost eye drops lists gradual eyelash changes—increased length, thickness, pigmentation and number of lashes—as a known effect, usually reversible after stopping. This raised the question: could the same principle work on scalp follicles? The scalp, however, is not just a larger version of the eyelid. It is a broader surface with thicker skin, different vascularization, and higher total exposure. That difference is exactly why side effects must be critically examined.

Local reactions: what happens on the scalp itself

The local effects that can be anticipated come mostly from ophthalmology. The latanoprost label reports itching, burning and stinging among the most common reactions at the eye, along with redness. On the scalp, similar redness, itching and burning are what one would expect, but no study has measured them. Pigmentation change is the other one to know about. The label states that pigmentation of the iris, of the periorbital tissue (eyelid) and of the eyelashes can occur, and that iris pigmentation is likely to be permanent. It lists darkening of the iris, eyelid skin and eyelashes among the most frequently reported changes (section 5.1). Whether skin darkening on the scalp would behave the same way has not been studied, so a reader should treat it as an open risk rather than a known one.

Changes in the hair's quality also deserve attention. Around the eye, prostaglandin analogues are reported to make new hair longer, darker and thicker than the hair it replaces. On the scalp, no published study reports on texture or colour mismatch, so whether treated patches would look different from surrounding hair is unknown. It is raised here as a plausible concern, not as a documented outcome.

Beyond the scalp: systemic absorption and its risks

The concern that latanoprost could enter the bloodstream through scalp application is not unfounded. In the eye, the drug is delivered in microgram doses — one drop of the 0.005% solution is roughly 1.5 micrograms — with minimal systemic absorption. On the scalp, the amount used would inevitably be greater, and the skin barrier is different. Even at ophthalmic doses the label records some systemic reactions: upper respiratory tract infection or flu-like symptoms in about 3% of patients and muscle, joint or back pain in about 1%, with further reactions collected after marketing. If a larger amount were absorbed through the scalp, whether those or other effects would become more frequent is simply unknown, because no study has measured it.

Pregnancy

There are no human data on latanoprost in pregnancy. The label states that in animal studies, latanoprost given during pregnancy caused malformations, embryo-fetal death and miscarriage at clinically relevant doses (section 8.1). Scalp use could expose the body to far more drug than the eye drop, so it should not be used off-label by anyone who is pregnant or could become pregnant.

Research evidence: what studies actually found

The interest in latanoprost for the scalp rests on very few studies. In 2012, Blume-Peytavi and colleagues carried out a randomized, double-blind, placebo-controlled pilot trial on 16 men with androgenetic alopecia over 24 weeks, using latanoprost 0.1% — twenty times the strength of the licensed eye drop. They assessed hair density photographically and reported greater density in latanoprost-treated areas than in placebo areas. The study is limited by its small population, short duration, and lack of follow-up on pigmentation changes or systemic effects (Blume-Peytavi et al., 2012).

Animal work is older and also small. Uno and colleagues applied topical latanoprost to the bald scalp of stump-tailed macaques in a pilot study published in 2002. In 8 monkeys, the eye-drop strength (50 µg/mL) for 5 months caused minimal hair growth; only a tenfold higher strength, given to 2 monkeys for a further 3 months, produced moderate to marked regrowth. The limitation is obvious: a small animal pilot cannot be assumed to replicate human outcomes, particularly with long-term exposure, and it was not designed to answer safety questions.

No published case series could be verified of latanoprost used on the human scalp, and no controlled study reporting scalp tolerability was found. That absence is itself the most important finding in this section.

The collective evidence points to one conclusion: latanoprost affects eyelash growth and may affect scalp hair, based on one 16-man pilot and animal work, but its side-effect profile on the scalp has not been measured. Irritation, pigmentation changes, and unpredictable cosmetic outcomes are plausible and not trivial. The larger question—systemic absorption over a large treated area—remains unanswered because the existing studies are too short, too small, or limited to animals. What is known about its use in the eye cannot be transferred to the scalp, given the differences in application area and dose. Until larger and longer trials exist, the drug remains an experimental option for the scalp, and the risks have not been quantified.

Latanoprost is a prescription eye drop approved only for glaucoma and raised eye pressure, and any scalp use is off-label, with no approved product, no established dose and no safety data at that surface area. Talk to a doctor or pharmacist before starting, stopping or combining latanoprost, and see a doctor if you develop skin irritation, skin darkening, or eye symptoms while using it.

References

Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology, 66(5), 794–800. https://pubmed.ncbi.nlm.nih.gov/21875758/

Uno, H., Zimbric, M. L., Albert, D. M., & Stjernschantz, J. (2002). Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macaque: a pilot study. Acta Dermato-Venereologica, 82(1), 7–12. https://pubmed.ncbi.nlm.nih.gov/12013211/

U.S. National Library of Medicine, DailyMed. XALATAN (latanoprost ophthalmic solution) 0.005% — prescribing information (Warnings and Precautions 5.1; Use in Specific Populations 8.1). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a98595b3-9f47-48e0-b18d-550a2095f264

U.S. National Library of Medicine, DailyMed. Latanoprost ophthalmic solution — prescribing information (Warnings and Precautions 5.1–5.2; Adverse Reactions 6.1–6.2). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c87e99e-33d4-4060-8876-ff05557c05eb